Human epidermal growth factor receptor 2 (HER2) is an overexpressed antigen in esophageal squamous cell carcinomas (ESCCs) but with limited expression levels in normal esophageal tissues. Therefore, employing the adoptive transfer of T cells genetically modified to express chimeric antigen receptor (CAR) targeting HER2 could be a promising therapeutic strategy against ESCC.
Methods:
Two different second-generation CAR-T cells expressing antibodies for HER2 and CD19 antigens were developed using retroviral vector transduction. The expression of HER2 antigen in ESCC tissue and cell lines was examined by immunohistochemistry and flow cytometry, respectively. The tumor killing efficacy of the CAR-T cells in mice model and ESCC cell lines and its potential for the treatment of ESCC was evaluated by determining tumor size in mice xenograft, and by crystal violet staining, MTS assay, and cytokine release.
Results:
In vitro, HER2.CAR-T cells efficiently recognized and killed HER2-positive tumor cells as evidenced by the secretion of proinflammatory cytokines, interferon-γ, and interleukin 2 and by cytotoxicity assays. In vivo, intratumor injection of HER2.CAR-T cells resulted in a significant suppression of established ESCCs in a subcutaneous xenograft BALB/c nude mouse model. In contrast, the injection of CD19.CAR-T cells did not affect the tumor growth pattern.
Conclusions:
An effective HER2 CAR targeting ESCC was developed successfully. The HER2.CAR-T cell showed promising immunotherapeutic potential for the treatment of HER2-positive esophageal cancer.
BrayFFerlayJSoerjomataramI, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin2018; 68: 394–424.
3.
YangCSChenXTuS.Etiology and prevention of esophageal cancer. Gastrointest Tumors2016; 3: 3–16.
4.
MalhotraGKYanalaURavipatiA, et al. Global trends in esophageal cancer. J Surg Oncol2017; 115: 564–579.
5.
LiuC-YWangB-YLeeM-Y, et al. The prognostic value of circumferential resection margin in esophageal squamous cell carcinoma after concurrent chemoradiation therapy and surgery. J Chin Med Assoc2013; 76: 570–575.
6.
BerryMF.Esophageal cancer: staging system and guidelines for staging and treatment. J Thorac Dis2014; 6Suppl 3: S289–S297.
7.
TanakaYYoshidaKSuetsuguT, et al. Recent advancements in esophageal cancer treatment in Japan. Ann Gastroenterol Surg2018; 2: 253–265.
8.
RestifoNPDudleyMERosenbergSA.Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol2012; 12: 269.
9.
MorganRADudleyMEWunderlichJR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science2006; 314: 126–129.
10.
RosenbergSA.Cell transfer immunotherapy for metastatic solid cancer: what clinicians need to know. Nat Rev Clin Oncol2011; 8: 577.
11.
LeeDWKochenderferJNStetler-StevensonM, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet2015; 385: 517–528.
12.
Von StackelbergALocatelliFZugmaierG, et al. Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol2016; 34: 4381–4389.
13.
FraiettaJALaceySFOrlandoEJ, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med2018; 24: 563–571.
14.
GeyerMBRivièreISénéchalB, et al. Autologous CD19-targeted CAR T cells in patients with residual CLL following initial purine analog-based therapy. Mol Ther2018; 26: 1896–1905.
15.
BaoFWanWHeT, et al. Autologous CD19-directed chimeric antigen receptor T cell is an effective and safe treatment to refractory or relapsed diffuse large B-cell lymphoma. Cancer Gene Ther2019; 26: 248–255.
16.
RamosCARouceRRobertsonCS, et al. In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B cell non-Hodgkin’s lymphomas. Mol Ther2018; 26: 2727–2737.
17.
SchusterSJBishopMRTamCS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med2018; 380: 45–56.
18.
GuhaPRehaJKatzSC.Immunosuppression in liver tumors: opening the portal to effective immunotherapy. Cancer Gene Ther2016; 24: 114.
19.
YuMLuoHFanM, et al. Development of GPC3-specific chimeric antigen receptor-engineered natural killer cells for the treatment of hepatocellular carcinoma. Mol Ther2018; 26: 366–378.
20.
BrownCEAlizadehDStarrR, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med2016; 375: 2561–2569.
21.
GolinelliGGrisendiGPrapaM, et al. Targeting GD2-positive glioblastoma by chimeric antigen receptor empowered mesenchymal progenitors. Cancer Gene Ther2018; 27: 558–570.
22.
ZhangCWangZYangZ, et al. Phase I escalating-dose trial of CAR-T therapy targeting CEA+ metastatic colorectal cancers. Mol Ther2017; 25: 1248–1258.
23.
MageeMSAbrahamTSBaybuttTR, et al. Human GUCY2C-targeted chimeric antigen receptor (CAR)-expressing T cells eliminate colorectal cancer metastases. Cancer Immunol Res2018; 6: 509–516.
24.
DohertyJKBondCJardimA, et al. The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor. Proc Natl Acad Sci USA1999; 96: 10869–10874.
25.
NataliPGNicotraMRBigottiA, et al. Expression of the p185 encoded by her2 oncogene in normal and transformed human tissues. Int J Cancer1990; 45: 457–461.
26.
MariaAMEl-ShebineyMEl-SakaAM, et al. Expression of truncated HER2 and its prognostic value in HER2-positive breast cancer patients. J Egypt Natl Cancer Inst2018; 30: 49–55.
27.
IqbalNIqbalN.Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int2014; 2014: 852748.
28.
LiXZhaoHGuJ, et al. Prognostic and clinicopathological significance of HER2 overexpression in pancreatic cancer: a meta-analysis. Int J Clin Exp Med2016; 9: 5699–5708.
29.
MimuraKKonoKHanawaM, et al. Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer2005; 92: 1253.
30.
MimuraKKonoKMaruyamaT, et al. Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines. Int J Cancer2011; 129: 2408–2416.
31.
KiesgenSChicaybamLChintalaNK, et al. Chimeric antigen receptor (CAR) T-cell therapy for thoracic malignancies. J Thorac Oncol2018; 13: 16–26.
32.
NairRNeelapuSS.The promise of CAR T-cell therapy in aggressive B-cell lymphoma. Best Pract Res Clin Haematol2018; 31: 293–298.
33.
AhmedNRatnayakeMSavoldoB, et al. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res2007; 67: 5957–5964.
34.
ShiHYuFMaoY, et al. EphA2 chimeric antigen receptor-modified T cells for the immunotherapy of esophageal squamous cell carcinoma. J Thorac Dis2018; 10: 2779–2788.
35.
BoyiadzisMMDhodapkarMVBrentjensRJ, et al. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. J Immunother Cancer2018; 6: 137.
36.
MageeMSAbrahamTSBaybuttTR, et al. Human GUCY2C-targeted chimeric antigen receptor (CAR)-expressing T cells eliminate colorectal cancer metastases. Cancer Immunol Res2018; 6: 509–516.
37.
YekuOOBrentjensRJ.Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy. Biochem Soc Trans2016; 44: 412–418.
38.
FeinsSKongWWilliamsEF, et al. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol2019; 94: S3–S9.
39.
ZhangQPingJHuangZ, et al. CAR-T cell therapy in cancer: tribulations and road ahead. J Immunol Res2020; 2020: 1924379.
40.
GuedanSMadarACasado-MedranoV, et al. Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability. J Clin Invest2020; 130: 3087–3097.
41.
AhmedNBrawleyVSHegdeM, et al. Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol2015; 33: 1688–1696.
42.
PorterDLLevineBLBuninN, et al. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood2006; 107: 1325.
43.
AkceMZaidiMYWallerEK, et al. The potential of CAR T cell therapy in pancreatic cancer. Front Immunol2018; 9: 2166–2166.
LiXChenW.Mechanisms of failure of chimeric antigen receptor T-cell therapy. Curr Opin Hematol2019; 26: 427–433.
46.
ChengJZhaoLZhangY, et al. Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies. Front Oncol2019; 9: 1237.
47.
ByrneMOluwoleOOSavaniB, et al. Understanding and managing large B cell lymphoma relapses after chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant2019; 25: e344–e351.
